Quoin Pharmaceuticals ( NASDAQ:QNRX – Get Free Report ) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.
Other equities research analysts have also issued reports about the stock. Lake Street Capital began coverage on shares of Quoin Pharmaceuticals in a report on Wednesday, September 23rd. They set a “buy” rating and a $20.00 target price on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research note on Friday, October 16th. Canaccord Genuity Group initiated coverage on shares of Quoin Pharmaceuticals in a research note on Monday, October 19th. They set a “buy” rating and a $18.00 price target for the company. Finally, BTIG Research began coverage on shares of Quoin Pharmaceuticals in a report on Monday, October 12th. They set a “buy” rating and a $14.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $17.33.
Get Quoin ...